The deleterious effects of iron overload in patients with myelodysplastic syndromes

Blood Reviews

Volumn 22, Issue SUPPL. 2, 2008, Pages

  Dreyfus, François ^a  

^a Service d'Hématologie A   (France)

Author keywords

Cardiac dysfunction; Cardiac iron overload; Iron chelation therapy; Myelodysplastic syndromes; Transfusion therapy

Indexed keywords

DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT;

BETA THALASSEMIA; BLOOD TRANSFUSION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; FERRITIN BLOOD LEVEL; HEART FAILURE; HEMOCHROMATOSIS; HEMOSIDEROSIS; HUMAN; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

BLOOD TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 57049141062     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(08)70006-7     Document Type: Review

References (34)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
2. Penninx B.W., Guralnik J.M., Onder G., et al. Anemia and decline in physical performance among older persons. Am J Med 115 (2003) 104-110
3. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
4. Wu W.C., Rathore S.S., Wang Y., et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 (2001) 1230-1236
5. Oliva E.N., Dimitrov B.D., Benedetto F., et al. Haemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 29 (2005) 1217-1219
6. Cazzola M., and Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352 (2005) 536-538
7. Malcovati L., Della Porta M.G., and Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91 (2006) 1588-1590
8. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 15 3 (2008 May) 169-175
9. Winder A., Lefkowitz R., Ghoti H., et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol 142 4 (2008 Aug) 669-671
10. Brittenham G.M., Olivieri N.F., and Roualt T.A. Iron physiology and iron overload (1996), American Society of Hematology, Education Programme 177
11. Grootveld M., Bell J.D., Halliwell B., et al. Non transferrin-bound iron in plasma or serum from patients with idiopathic haemochromatosis. J Biol Chem 264 (1989) 4417-4422
12. Breuer W., Greenberg E., and Cabantchik Z.I. Newly delivered transferrin iron and oxidative cell injury. FEBS Lett 403 (1997) 213
13. Cortelezzi A., Cattaneo C., Cristiani S., et al. Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 1 (2000) 153-158
14. Schafer A.I., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304 (1981) 319-324
15. Buja L.M., and Roberts W.C. Iron in the heart. Etiology and clinical significance. Am J Med 51 (1971) 209-221
16. Jaeger M., Aul C., Söhngen D., et al. Sekundäre Hämochromatose bei polytransfundierten Patienten mit myelodysplastischen Syndromen. Beits Infusionsther 30 (1992) 464-468
17. Mathew P., Tefferi A., Dewald G.W., et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood 81 (1993) 1040-1045
18. Takatoku M., Uchiyama T., Okamoto S., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anaemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78 (2007) 487-494
19. Goldberg S.L., Mody-Patel N., and Warnock N. Incidence of myelodysplastic syndromes in the United States Medicare population. Leuk Res 31 Suppl 1 (2007) S103 [abstract].
20. Della Porta M.G., Malcovati L., Travaglino E., et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Blood 110 (2007) abstract 2453.
21. Deschler B., de Witte T., Mertelsham R., et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: problems and approaches. Haematologica 91 (2006) 1513-1522
22. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101 (2003) 4632-4639
23. Chacko J., Pennell D.J., Tanner M.A., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 (2007) 587-593
24. Konen E., Ghoti H., Goitein O., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 82 (2007) 1013-1016
25. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2- star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001) 2171-2179
26. Glanville J., Eleftheriou P., and Porter J.B. MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias [abstract]. Blood 108 (2006) 1553
27. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994) 574-578
28. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31 Suppl 3 (2007) S7-S9
29. Rose C., Brechignac S., Vassilief D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110 (2007) abstract 249.
30. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87 (2002) 1286-1306
31. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 120 (2003) 187-200
32. Gattermann N., Porter J.B., Lopes L.F., et al. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 19 Suppl 1 (2005) 18-25
33. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines. Myelodysplastic Syndromes, v.2.2008 (2008). www.nccn.org
34. Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin North Am 19 Suppl 1 (2005) 13-17